Axsome Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 6 Sell calls were actually followed by a +12% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -23.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 6.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 73.8x | Better than 4% |
| Price / Sales | 8.6x | Better than 12% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 92.6% | Better than 97% |
| Operating margin | -26.5% | Better than 11% |
| Net margin | -28.7% | Better than 11% |
| Return on equity | -252.1% | Better than 2% |
| Return on invested capital | -63.5% | Better than 4% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -37.7% | Better than 12% |
| 6-month return | -45.2% | Better than 9% |
| 12-month return (ex latest month) | -2.9% | Better than 31% |
| Distance below 52-week high | 50.3% | Better than 18% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.6x | Better than 43% |
| Debt to assets | 31.6% | Better than 39% |
| Interest coverage | -27.0x | Better than 9% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 94.1% | Better than 77% |
| Upside to average target | 104.0% | Better than 84% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 135.68
- Open
- 133.92
- Day range
- 128.23 - 135.09
- Avg price
- 130.33
- Volume
- 811.79K
- Turnover
- 105.80M
- Turnover ratei
- 1.82%
- Volume ratioi
- 1.00
- Amplitudei
- 5.06%
- 52-week rangei
- 123.00 - 260.19
Valuation
- P/Ei
- -35.15
- P/E (TTM)i
- -42.69
- P/Bi
- 64.55
- EPSi
- -3.68
- Book value / shi
- 2.00
- Net profit
- -193.57M
- Net assets
- 105.41M
Share structure
- Market cap
- 6.80B
- Float capi
- 5.78B
- Shares out
- 52.60M
- Float sharesi
- 44.68M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-11-19
50.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.87M net over the window
Short interest
- Shares short
- 3.26M
- % of floati
- 6.23%
- Days to coveri
- 3.35
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Axsome Therapeutics (AXSM)?
Axsome Therapeutics last traded at 129.36. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Axsome Therapeutics's market cap?
About 6.80B.
What is the P/E ratio of Axsome Therapeutics?
The trailing twelve-month P/E is -42.69. The Valuation tab shows it against the stock's own five-year range.
Does Axsome Therapeutics pay a dividend?
Axsome Therapeutics does not currently pay a regular dividend.
Is Axsome Therapeutics a buy according to analysts?
The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 263.94, which implies 104.0% upside from the current price. This is not investment advice.
What is Axsome Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Axsome Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Axsome Therapeutics discussion 0 comments